Protagonist Therapeutics Inc
PTGX64.830USD
-0.150-0.23%
Cierre 10/03, 16:00（ET）Cotizaciones retrasadas 15 min
4.01BCap. mercado
10.01P/E TTM
Más Datos de Protagonist Therapeutics Inc Compañía
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Información de Protagonist Therapeutics Inc
Símbolo de cotizaciónPTGX
Nombre de la empresaProtagonist Therapeutics Inc
Fecha de salida a bolsaAug 11, 2016
Director ejecutivoDr. Dinesh V. Patel, Ph.D.
Número de empleados126
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 11
Dirección7707 Gateway Blvd Ste 140
CiudadNEWARK
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94560-1160
Teléfono15104740170
Sitio Webhttps://www.protagonist-inc.com/
Símbolo de cotizaciónPTGX
Fecha de salida a bolsaAug 11, 2016
Director ejecutivoDr. Dinesh V. Patel, Ph.D.
Ejecutivos de Protagonist Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.60K
-0.20%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-100.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.60K
-0.20%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 28 de sep
Actualizado: dom., 28 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.60%
Farallon Capital Management, L.L.C.
9.92%
RTW Investments L.P.
9.25%
The Vanguard Group, Inc.
6.99%
Deep Track Capital LP
5.22%
Otro
55.03%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.60%
Farallon Capital Management, L.L.C.
9.92%
RTW Investments L.P.
9.25%
The Vanguard Group, Inc.
6.99%
Deep Track Capital LP
5.22%
Otro
55.03%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
41.23%
Hedge Fund
31.78%
Investment Advisor/Hedge Fund
30.47%
Research Firm
5.59%
Venture Capital
3.95%
Private Equity
1.83%
Pension Fund
1.09%
Individual Investor
1.02%
Bank and Trust
0.37%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
542
72.38M
116.35%
-3.16M
2025Q2
533
68.00M
109.30%
-9.94M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
2023Q2
411
59.30M
103.68%
-17.88M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
8.46M
13.6%
-140.21K
-1.63%
Jun 30, 2025
Farallon Capital Management, L.L.C.
6.17M
9.92%
+65.00K
+1.06%
Jun 30, 2025
RTW Investments L.P.
5.76M
9.25%
+36.86K
+0.64%
Jun 30, 2025
The Vanguard Group, Inc.
4.35M
6.99%
+80.38K
+1.88%
Jun 30, 2025
Deep Track Capital LP
3.25M
5.22%
-4.10K
-0.13%
Jun 30, 2025
BVF Partners L.P.
3.21M
5.16%
+636.03K
+24.70%
Jun 30, 2025
State Street Global Advisors (US)
3.21M
5.16%
+500.92K
+18.51%
Jun 30, 2025
UBS Financial Services, Inc.
2.50M
4.02%
+2.15M
+619.02%
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.94%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.44M
2.32%
+20.67K
+1.45%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 2 de oct
Actualizado: jue., 2 de oct
Nombre
Proporción
Invesco Biotechnology & Genome ETF
3.28%
Invesco Dorsey Wright Healthcare Momentum ETF
2.8%
Invesco S&P SmallCap Health Care ETF
2.47%
ALPS Medical Breakthroughs ETF
2.14%
Invesco S&P SmallCap 600 Pure Growth ETF
2.05%
ETC 6 Meridian Small Cap Equity ETF
1.58%
SPDR S&P Biotech ETF
1.15%
Cambria Value and Momentum ETF
0.93%
Virtus LifeSci Biotech Clinical Trials ETF
0.82%
Direxion Daily S&P Biotech Bull 3X Shares
0.7%
Ver más
Invesco Biotechnology & Genome ETF
Proporción3.28%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción2.8%
Invesco S&P SmallCap Health Care ETF
Proporción2.47%
ALPS Medical Breakthroughs ETF
Proporción2.14%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporción2.05%
ETC 6 Meridian Small Cap Equity ETF
Proporción1.58%
SPDR S&P Biotech ETF
Proporción1.15%
Cambria Value and Momentum ETF
Proporción0.93%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.82%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.7%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
